This trial will study the effects of nedosiran in children with Primary Hyperoxaluria, a kidney disease.
- Primary Hyperoxaluria
- Primary Hyperoxaluria Type 3
- Primary Hyperoxaluria Type 1
- Primary Hyperoxaluria Type 2
2 Primary · 24 Secondary · Reporting Duration: 180 days
1 Treatment Group
1 of 1
20 Total Participants · 1 Treatment Group
Primary Treatment: nedosiran · No Placebo Group · Phase 2
Who is running the clinical trial?
Age < 18 · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants can potentially join this trial?
"Affirmative, the information available on clinicaltrials.gov indicates that this study is still in progress. Initially posted on February 22nd 2022 and recently modified on November 30th 2022, it aims to recruit 20 people from 3 different medical centres." - Anonymous Online Contributor
To what extent is nedosiran hazardous to human health?
"Nedosiran has been assigned a score of 2, as there is evidence to suggest it is safe but no clinical trials have yet tested its efficacy." - Anonymous Online Contributor
What are the primary aims of this clinical research project?
"This clinical trial is scheduled to last for 180 days and will measure the efficacy of a particular medical intervention via % change in urinary oxalate-creatinine ratio. Secondary goals include characterizing safety using changes from baseline in laboratory tests, blood pressure readings, and individual pharmacokinetic parameters (AUC)." - Anonymous Online Contributor
Are there still opportunities for applicants to join this medical experiment?
"Affirmative. The information on clinicaltrials.gov reveals that the trial is actively seeking participants; this study, which was initially posted on February 22nd 2022, has been recently modified as of November 30th 2022." - Anonymous Online Contributor